Article Text
Statistics from Altmetric.com
- liver fibrosis
- non-invasive assessment
- chronic hepatitis B
- gamma-glutamyl transpeptidase to platelet ratio
- diagnostic performance
We read with interest the study by Lemoine et al1 in which the gamma-glutamyl transpeptidase (GGT) to platelet ratio (GPR) was developed to stage fibrosis in patients with chronic hepatitis B (CHB). This study concluded that GPR is more accurate than the aspartate aminotransferase to platelet ratio index (APRI) and Fib-4 to stage liver fibrosis in patients with CHB. As China is a highly endemic area of CHB with estimated >74 million hepatitis B surface antigen (HBsAg)-positive patients,2 3 we conducted this multicentre study to validate the diagnostic performance of GPR in Chinese patients with CHB.
Treatment-naïve patients with positive HBsAg who underwent liver biopsy, Fibroscan (FS402, Echosens, France) and blood tests were included from three centres (Huai’an Fourth People’s Hospital, Huai’an, China (January 2012–April 2016), Beijing You-An Hospital, Capital Medical University, Beijing, China (January 2014–June 2016) and Hepatology Hospital of Jilin …
Footnotes
Contributors X-JL and BS led the research programme; X-JL and XZ conceived the idea; XZ, X-HL and Z-XY were principal investigators of participant centres; H-YS, X-CW and XQ collected and analysed the data; X-JL wrote the manuscript and BS made critical revisions.
Funding This study was supported by the National Key Research and Development Program of China under Grant no 2016YFC0905900 to BS and the Natural Science Foundation of China (NO.81772596 to X-JL).
Competing interests None declared.
Patient consent Obtained.
Ethics approval Ethics Committee of Huai’an Fourth People’s Hospital (Huai’an, China); Ethics Committee of Beijing You-An Hospital, Capital Medical University (Beijing, China); Ethics Committee of Hepatology Hospital of Jilin Province (Jilin, China).
Provenance and peer review Not commissioned; internally peer reviewed.